Title: Differential region-specific regulation of $\alpha 4\beta 2^*$ nAChRs by self-administered and non-contingent nicotine in C57BL/6J mice

Athanasios Metaxas^a, Alexis Bailey^a, Maria Flavia Barbano^b, Lola Galeote^b, Rafael Maldonado^b, Ian Kitchen^a

^a Faculty of Health & Medical Sciences, Division of Biochemical Sciences, University of Surrey, Guildford, GU2 7XH, Surrey, UK

^b Laboratori de Neurofarmacologia, Facultat de Ciències de la Salut i de la Vida, Universitat Pompeu Fabra, Carrer del Dr. Aiguader 80, 08003, Barcelona, Spain

Corresponding author: Athanasios Metaxas

VU University Medical Center

Nuclear Medicine & PET Research

Location Radionuclide Centre

De Boelelaan 1085 c, 1081 HV Amsterdam

Tel: +31 (0)20-4449704; Email: a.metaxas@vumc.nl

ABSTRACT

Neuronal nAChR upregulation is the hallmark of chronic nicotine exposure. Neuroplasticity to abused drugs, however, depends on whether their administration is forced by the experimenter or is under the control of the experimental animal. Neuroadaptation to chronic nicotine self-administration was examined with a yoked-control paradigm, using nose-poking as the operating procedure. Freely moving C57BL/6J mice that responded for 0.03 mg/kg/infusion of intravenous nicotine under a continuous schedule of reinforcement (FR-1), had control over the rate and amount of drug intake that a yoked littermate passively received (n=11). The impact of response dependency on neurobiological changes in nicotinic and dopaminergic systems was subsequently assessed using quantitative autoradiography. Cytisine-sensitive [¹²⁵I]epibatidine binding, [³H]SCH23390, [³H]raclopride, and [³H]mazindol were used to label nAChRs with $\alpha 4\beta 2^*$ subtype properties, D1 and D2 dopaminergic receptors, and dopamine transporters, respectively. During a period of 12 days, self-administration was reliably initiated and maintained in animals receiving response-contingent nicotine. Region specific changes in the density of $\alpha 4\beta 2^*$ nAChRs were found to be dependent on the contingency of nicotine treatment. Higher levels of $\alpha 4\beta 2^*$ receptor binding were observed in the dorsal lateral geniculate nucleus and the ventral tegmental area of self-administering mice, compared to non-contingent animals. Moreover, response-independent increases in D2 binding were observed following chronic nicotine administration. No change in D1 and DAT binding was observed among groups. These findings indicate regional specific alterations in the regulation of the nicotinic cholinergic system following contingent and non-contingent nicotine exposure, and underline the importance of response dependency on the development of nicotine addiction.

Keywords: autoradiography, mouse, nicotine, operant contingency, self-administration

INTRODUCTION

Nicotine exerts its reinforcing effects by binding in the brain to its corresponding pharmacological targets, the neuronal nicotinic receptors (nAChRs). These are a heterogeneous family of pentameric structures, formed by the assembly of five α and β subunits. To date twelve different subunits have been identified ($\alpha 2$ - $\alpha 10$, $\beta 2$ - $\beta 4$), whose combinations give rise to nAChRs with unique pharmacological properties and distinct topographical distribution (reviewed in Gotti and Clementi, 2004). **This prominent heterogeneity mediates nicotine's abuse related potential, as the drug has been shown to differentially coordinate the function of distinct nAChR subtypes, thereby stimulating reward-related signaling in areas of the brain that mediate reinforcement** (Pidoplichko et al., 1997; Mansvelder and McGehee, 2000; Mansvelder et al., 2002). Nevertheless, the transition from the activation of individual nAChR subpopulations to addiction is a complicated and multistage process, which involves the acquisition, maintenance, extinction, and reinstatement of drug-taking. **Therefore, behavioural paradigms that model distinct stages of addictive behaviour provide important methodological tools for determining the neurobiological substrates that mediate the progression to nicotine addiction.**

The observation that the administration of nicotine leads to increased brain nAChR density in cigarette smokers (Perry et al., 1999) and in animal models of nicotine consumption (Marks et al., 1983; Schwartz and Kellar, 1983) constitutes the hallmark of chronic nicotine exposure. **This unusual phenomenon of agonist-induced receptor upregulation is considered to form the basis for many of nicotine's abuse-related effects, including tolerance and behavioural sensitisation** (Tapper et al., 2004; Nashmi et al., 2007). Of the multiple nicotinic subtypes that exist in the

mammalian brain, $\alpha 4\beta 2^*$ receptors are abundantly expressed throughout the central nervous system, and they readily upregulate following exposure to nicotine, compared with other nAChR subtypes (Nguyen et al., 2003; Marks et al., 2004). As shown in a conditioned place preference paradigm, a mutation that renders $\alpha 4$ subunits hypersensitive to agonists creates mice that are more susceptible to nicotine reinforcement than wild type animals (Tapper et al., 2004). Moreover, deletion of the $\beta 2$ subunit gene attenuates nicotine self-administration (Picciotto et al., 1998) and its re-expression in the VTA of $\beta 2$ subunit knockout animals re-establishes the behaviour (Maskos et al., 2005). Altogether, these data demonstrate an important role for $\alpha 4\beta 2^*$ nAChRs in nicotine addiction.

Among the paradigms employed to model different aspects of drug reinforcement, self-administration has been favoured as the most direct way of investigating the behavioural and neurobiological processes that lead to addiction. Its face validity is supported by increasing evidence, which suggests that drugs of abuse exert different effects, depending on whether their administration is forced by the experimenter or is under the control of the experimental animal (reviewed in Jacobs et al., 2003). The yoked-control paradigm has been particularly designed to examine differences produced by the active or passive drug administration. In this model, self-administering animals have control over the rate and amount of drug intake that a yoked littermate passively receives in an identical environment. Thus, potential differences in the consequences of active versus passive administration can be attributed to having control over the pattern of drug exposure. To determine the extent to which nicotine-induced neuroadaptation is the consequence of the drug's direct pharmacological action or the result of the contingency between a subject's response

and the delivery of a reinforcer, a yoked-control paradigm of chronic nicotine administration in mice was employed, using nose-poking as the operating response. The latter is considered to more naturally mimic smoking behaviour in mice, requiring less motor and motivational output than lever pressing responding (Pons et al., 2008). Subsequently, we examined the consequences of active versus passive nicotine exposure on the nicotinic cholinergic and dopaminergic systems of C57BL/6J mice by means of quantitative autoradiography of cytosine-sensitive heteromeric nicotinic receptors, D1 and D2 dopaminergic receptors, and of dopamine transporters, in an effort to clarify the neurochemical determinants that mediate the acquisition of nicotine self-administration.

MATERIALS AND METHODS

Self administration paradigm

Animals

C57BL/6J male mice (Charles River, France), weighing 24-26 g at the beginning of the study were used. Animals were housed **individually** in controlled laboratory conditions under a reversed 13h/11h dark/light cycle (lights off at 7.30h, lights on at 20.30h), with the temperature maintained at 21 ± 1 °C, and humidity at $55 \pm 10\%$. **The circadian cycle employed allowed us to maximize the time required to perform the experimental manipulations without substantial modifications of the 12h/12h cycle commonly used.** Mice were tested during the dark phase of the dark/light cycle. Food and water were available *ad libitum*, except during the experimental sessions. Animal procedures were conducted in accordance with the guidelines of the European Communities Directive 86/609/EEC regulating animal research, and approved by the local ethical committee (CEEA-IMAS-UPF).

Surgery and self-administration procedure

Mice were anaesthetised with a mixture of ketamine (100 mg/kg; Imalgène 1000; Rhône Mérieux, Lyon, France) and xylazine (20 mg/kg; Sigma, Madrid, Spain), and then implanted with indwelling i.v. catheters as previously described (Soria et al., 2005). Following surgery, all incisions were sutured and coated with antibiotic ointment (Bactroban, GlaxoSmithKline, Spain), and animals were allowed to recover for 3 days. Mice were subsequently randomly assigned to contingent or yoked groups.

Drug self-administration experiments were conducted in mouse operant chambers (Model ENV-307A-CT, Medical Associates, Georgia, VT, USA), housed in sound- and light-attenuated boxes that were equipped with fans to provide ventilation and white noise. The house light was on at the beginning of the session for 3 sec and off during the remaining time. The chambers were equipped with two holes, of which one was selected as the active and the other as the inactive hole. Responding in both holes was recorded for all groups, throughout the experiments. The contingent group was trained to self-administer nicotine (0.03 mg/kg/infusion delivered in a volume of 23.5 µl over 2s; Sigma, Madrid, Spain) in single daily 1-h sessions for a period of 12 days. **Even though nicotine self-administration is already acquired after 10 days of training (Martín-García et al. 2009, Plaza-Zabala et al. 2010), we run the animals for 2 additional days in order to maximize stability in the observed behaviour and in the possible neural modifications under study. Previous experiments in our laboratory indicated that a priming injection at the beginning of the session facilitates the acquisition of nicotine self-administration (Martin-Garcia et al., 2009; Plaza-Zabala et al., 2010), so each session started with a priming injection of nicotine or saline (depending on the group). Acquisition of nicotine self-**

administration was conducted under a fixed ratio 1 (FR-1) schedule of reinforcement; one poke in the active nose hole resulted in one nicotine infusion, while nose poking in the inactive hole had no programmed consequences. A 10 sec time-out period was established following each nicotine infusion. During this period, responses on the active and inactive holes were recorded but had no programmed consequences. The session was terminated after 50 infusions had been delivered, or after one hour, whichever occurred first. Each contingent mouse was connected to two animals, one in the yoked nicotine and one in the yoked saline groups. Yoked mice passively received the same number of drug infusions as compared with their self-administration partners, at identical times during each session. Their nose-poking activity on the active and inactive holes had no consequences. A stimulus light located above the active hole was paired with the delivery of nicotine or saline, according to the response of the contingent mouse. **The patency of the intravenous catheters was evaluated periodically**, and whenever drug self-administration behaviour appeared to deviate dramatically from that observed previously, by the infusion of 0.1 ml of thiobarbital (5 mg/ml) through the catheter. If prominent signs of anaesthesia were not apparent within 3 sec of the infusion, **the mouse and its corresponding data were removed from the experiment**. The criteria for the acquisition of self-administration behaviour have been described previously (Orejarena et al., 2009; Trigo et al., 2009), and were achieved when all of the following conditions had been met: a stable responding, with less than 20% deviation from the mean of the total number of reinforcers earned in three consecutive sessions (80% of stability), at least 65% of responding on the active hole, and a minimum of 4 nicotine infusions earned per experimental session. After each session, animals were returned to their home cages. At the end of the study mice were

killed and brains were rapidly removed and frozen for storage at -80°C for subsequent quantitative autoradiography studies.

Quantitative receptor autoradiography

Tissue sectioning was carried out at -21°C using a Zeiss Microm HM505E cryostat. 20 μm frozen coronal sections were cut at 300 μm intervals, from rostral to caudal levels. Quantitative autoradiography was performed in order to measure nicotinic receptors with $\alpha 4\beta 2^*$ subtype properties, dopaminergic D1 and D2 receptors, and the dopamine transporters (DAT). On the day of each experiment, sections were thawed and processed according to established protocols, with minor modifications (Javitch et al., 1984; Marks et al., 2002; Lena et al., 2004; Bailey et al., 2008). **All mice were used for quantitative autoradiography of nAChRs. Dopaminergic receptor and transporter binding was performed in 3 self-administering mice that achieved acquisition criteria, 3 that did not, and their corresponding littermates (n=6 per group).** Multiple, adjacent sections from all groups were processed together in a paired binding protocol. Radioligand bound sections were apposed to Kodak BioMax MR-1 film (Sigma-Aldrich, UK), along with appropriate microscale standards, to allow quantification. All structures were identified by reference to the mouse brain atlas of Franklin and Paxinos, (2001), and analysed using a MCID image analyser (Image research, Linton, UK).

For nicotinic receptor binding, sections were pre-incubated for 10 min at room temperature in Tris-HCl buffer, containing 120 mM NaCl, 5 mM KCl, 2.5 mM CaCl_2 , and 1 mM MgCl_2 , pH 7.4, followed by incubation with 100 pM [^{125}I]epibatidine (specific activity, 2,200 Ci/mmol; PerkinElmer Life Sciences, Boston, MA, USA) for

two hours at room temperature. Determination of subtype-specific binding was performed using adjacent sections from each brain, in order to measure total [125 I]epibatidine binding (no competing ligand), and [125 I]epibatidine binding in the presence of 20 nM cytosine (Sigma-Aldrich, UK). Competition of [125 I]epibatidine binding by unlabeled cytosine has been used to reveal two subpopulations of nAChRs with high and low affinity for cytosine, termed cytosine-sensitive and cytosine-resistant [125 I]epibatidine binding sites, respectively. The cytosine-sensitive [125 I]epibatidine binding sites correspond to $\alpha 4\beta 2^*$ nicotinic receptors (Marks et al., 1998; Whiteaker et al., 2000), **and were calculated after the subtraction of cytosine-resistant from total [125 I]epibatidine binding.** To determine non-specific binding, further adjacent sections were incubated with [125 I]epibatidine in the presence of 300 μ M of (–) nicotine hydrogen tartrate (Sigma-Aldrich, UK). Incubations were terminated by two, ten minute washes into ice-cold 50 mM Tris-HCL buffer (pH 7.4), and a rapid rinse in ice-cold water. Radioligand bound sections were apposed to film for 24h. Structures of exceptionally high nAChR density, including the medial habenula, fasciculus retroflexus, and the interpeduncular nucleus were apposed for 6h, to avoid film saturation.

For D1 and D2 receptor binding, all sections were first pre-incubated for 20 min in 50 mM Tris–HCl buffer, pH 7.4, containing 120 mM NaCl, 5 mM KCl, 2 mM CaCl_2 and 1 mM MgCl_2 , at room temperature. For D1 binding, sections were then incubated for 90 min in the same buffer, at room temperature, in the presence of 4 nM [^3H]SCH23390 (specific activity, 70.3 Ci/mmol; PerkinElmer Life Sciences, Boston, MA, USA) and 1 μ M mianserin, in order to avoid binding of [^3H]SCH23390 to 5-HT $_2$ and 5-HT $_{1c}$ receptors. To label D2 receptors, incubation was carried out for 60 min in

the presence of 4 nM [³H]raclopride (specific activity, 60.1 Ci/mmol; PerkinElmer Life Sciences, Boston, MA, USA), under identical pH and temperature conditions. Non-specific binding was determined on adjacent sections in the presence of 10 µM of cis-flupenthixol for D1 receptors or 10 µM of sulpiride for D2 receptors. The incubations were terminated by rapid rinses (6×1 min) in ice-cold 50 mM Tris-HCl buffer (pH 7.4) followed by a dip into ice-cold distilled water. For D1 and D2 receptors, radioligand bound sections were apposed to film for 5 and 6 weeks, respectively.

For the DAT, all slides were pre-incubated for 5 min at 4°C in 50 mM Tris-HCl buffer, pH 7.4, containing 300 mM NaCl and 5 mM KCl. The slides were subsequently incubated at 4°C for 45 min in the same buffer, containing 4 nM [³H]mazindol (specific activity, 20.6 Ci/mmol; PerkinElmer Life Sciences, Boston, MA, USA) and 0.3 µM desipramine, to block the binding to norepinephrine uptake sites. Non-specific binding was determined in the presence of 10 µM mazindol. After incubation, sections were rinsed twice for 1 min in ice-cold Tris buffer, and briefly dipped in ice-cold distilled water. Sections were apposed to film for 5 weeks.

Statistical analysis

Behavioural results were analysed using a mixed-design multivariate analysis of variance (MANOVA), with group (contingent, non-contingent, and saline-treated) as the between-subjects variable. Daily sessions and hole (active vs. inactive) represented the within-subjects variable. Overall interactions were further analysed using the Newman-Keuls post-hoc test, when the initial P value was smaller than 0.05. All the results are expressed as mean ± standard error of the mean (SEM).

For quantitative autoradiography, the mean $\pm$ SEM of radioligand binding was calculated in each region for all three treatment groups, as previously described (Kitchen et al., 1997). Two-way ANOVA for the factors treatment and region was carried out in order to compare quantitative measurements of autoradiographic binding in brain areas of contingent, non-contingent, and saline-treated animals. Structures of the habenulo-interpeduncular pathway were quantified using the 6 h exposure to film, due to the high densities of heteromeric nAChRs in this cholinergic system. Therefore, comparisons between regions of exceptionally high nicotinic receptor density were performed using a separate two way ANOVA (independent factors treatment and region). **Quantitative differences in nicotinic and dopaminergic binding sites between self-administering mice that achieved acquisition criteria and those that did not were analysed using a separate two-way ANOVA, for the factors acquisition and region.** LSD post-hoc analysis was applied, when appropriate, to investigate differences in radioligand binding between groups in individual regions.

All data were analysed using the Statistica software (StatSoft Inc., France).

RESULTS

Nicotine self-administration

Figure 1 shows the mean number of nose-pokes in the active and inactive holes, carried out by nicotine contingent, non-contingent and saline-treated animals under an FR-1 schedule of reinforcement, for each of the 1hr daily self-administration sessions. At the nicotine dose of 0.03 mg/kg/infusion, contingent mice started to discriminate between the active and inactive holes from the first training session (Figure 1A). The percentage of animals that proceeded to complete all of the criteria for stable nicotine self-administration was 54.5% (six out of eleven), and the mean time of acquisition was 8.83 ± 1.19 days. On the contrary, nicotine- and saline- yoked mice did not discriminate between holes in any of the experimental sessions (Figure 1B and 1C). On days 1 and 2, the number of nose pokes was enhanced in all groups, compared to days 3-12. The mean nicotine intake decreased from 0.38 ± 0.01 mg/kg/hr on days 1 and 2, to 0.22 ± 0.01 mg/kg/hr for days 3-12. Contingent mice showed a mean cumulative nicotine intake of 0.25 ± 0.04 mg/kg/hr throughout the training sessions. In the case of the animals that achieved acquisition criteria, the mean intake of nicotine during the last three days of self-administration was 0.35 ± 0.09 mg/kg/hr. The overall ANOVA revealed a statistically significant effect of the factors group ($F_{2,58}=12.0$, $P<0.001$), time ($F_{11, 638}=15.2$, $P<0.001$), and nose-poke ($F_{1,58}=22.6$, $P<0.001$), as well as significant group x nose-poke interaction effects ($F_{2,58}=7.8$, $P<0.001$). Newman-Keuls post-hoc analysis confirmed that the responses on the active and inactive nose-pokes were significantly higher only in the contingent group and not in the yoked groups.

Quantitative receptor autoradiography

Effects of response contingency on nAChR binding

Quantitative autoradiography was conducted for $\alpha 4\beta 2^*$ nAChRs, using 100 pM of [125 I]epibatidine alone or in the presence of cytisine (20 nM). The majority of mouse brain [125 I]epibatidine binding sites were of the cytisine-sensitive, $\alpha 4\beta 2^*$ subtype. Non-specific [125 I]epibatidine binding was indistinguishable from film background (Figure 2). The density of cytisine-sensitive and cytisine-resistant [125 I]epibatidine binding in brain regions of saline, contingent, and non-contingent mice is detailed for all areas analysed in Tables 1 and 2, respectively. **Figure 3 shows representative autoradiograms of [125 I]epibatidine binding sites in coronal brain sections from saline and nicotine treated mice, cut at the level of the thalamus and of the ventral tegmental area.**

Significantly higher levels of $\alpha 4\beta 2^*$ nAChRs were observed in the dorsal lateral geniculate nucleus (DLG) and the VTA of self-administering mice, compared to non-contingent animals and to saline controls. Contingent nicotine also increased cytisine-sensitive [125 I]epibatidine binding in the superficial gray layers of the superior colliculus (SuG) and certain thalamic nuclei, such as the ventral lateral geniculate nucleus (VLG), the posterior thalamic nuclear group (Po), and the lateral posterior thalamic nucleus (LPMR), compared to saline treatment. In non-contingent animals, higher levels of $\alpha 4\beta 2^*$ receptor binding were observed in the VLG and SuG compared to saline controls. No differences in cytisine-sensitive [125 I]epibatidine binding sites were detected between contingent mice that achieved acquisition criteria, and animals that did not stably respond for nicotine ($F_{1,140}=1.8$, $P>0.05$). For nAChRs with $\alpha 4\beta 2^*$ nAChR properties, two-way ANOVA showed significant main effects of treatment

($F_{2,463}=20.4$, $P<0.001$) and region ($F_{17,463}=48.3$, $P<0.001$), with no treatment x region interaction effects ($F_{34,463}=1.2$, $P>0.05$). LSD post hoc analysis confirmed significant, region specific differences in cytosine-sensitive [125 I]epibatidine binding between self-administering and nicotine-yoked mice in the DLG and the VTA. Comparisons of cytosine-sensitive [125 I]epibatidine binding measurements between structures of high nicotinic receptor density revealed no treatment ($F_{2,43}=0.3$, $P>0.05$), and no treatment x region interaction effects between groups ($F_{4,43}=0.2$, $P>0.05$).

Cytosine-resistant [125 I]epibatidine binding sites represented the major nAChR population in areas of the habenulo-interpeduncular pathway, and the quantitative comparison of nAChR density in these brain regions revealed no treatment ($F_{2,45}=1.0$, $P>0.05$) or treatment x region interaction effect ($F_{4,45}=0.5$, $P>0.05$). Cytosine-resistant binding in the rest of brain regions analysed was significantly lower in the SuG, the intermediate gray layer of the superior colliculus (InG), and the substantia nigra pars compacta (SNs) of nicotine yoked animals, compared to saline controls. A lower level of cytosine-resistant binding was also observed in the InG of self-administering animals, compared to controls. Two way ANOVA confirmed significant main effects of treatment ($F_{2,463}=3.0$, $P<0.05$) and region ($F_{17,463}=216.8$, $P<0.001$), with significant treatment x region interaction effects on cytosine-resistant receptor density ($F_{34,463}=1.5$, $P<0.05$). No differences were detected between nicotine-contingent and yoked mice, in any of the brain regions analysed ($F_{1,140}=2.0$, $P>0.05$).

Effects of response contingency on dopaminergic D1 and D2 receptor, and on dopamine transporter binding

Full quantification of dopaminergic D1 and D2 receptor binding, and of the dopamine transporters (DAT) was carried out on brain sections from all treatment groups, using [3 H]SCH23390, [3 H]raclopride, and [3 H]mazindol, respectively. For D2 receptor binding, two-way ANOVA revealed significant main effects of treatment ($F_{2,95}=6.1$, $P<0.01$) and region ($F_{6,95}=74.4$, $P<0.001$), with no significant treatment $\times$ region interaction effect ($F_{12,95}=0.3$, $P>0.05$) (Table 3). There was an overall increase in D2 receptor binding across all regions, in both nicotine contingent and non-contingent mice, compared to saline controls. However, post hoc comparison revealed no individual region significant increase among groups. The small level of increase in D2 receptor density was observed in self-administering animals, as well as in contingent mice that did not fulfil acquisition criteria ($F_{1,24}=0.0$, $P>0.05$).

Neither response-dependent, nor passively received nicotine had any significant effects on dopamine D1 receptor ($F_{2,133}=2.6$, $P>0.05$) and dopamine transporter (DAT) binding ($F_{2,105}=2.0$, $P>0.05$), compared with saline treatment (Tables 4&5). Moreover, no changes in D1 receptor density ($F_{1,36}=0.2$, $P>0.05$) and DAT binding ($F_{1,28}=1.1$, $P>0.05$) were detected in brain sections from animals that stably responded for nicotine, compared to mice that did not achieve acquisition criteria. Representative autoradiograms of dopaminergic receptor and transporter bindings in brain sections of nicotine contingent, yoked, and saline-treated animals are shown in Figure 4.

DISCUSSION

Previous studies have shown that nicotine, at a concentration range between 0.01-0.05 mg/kg/infusion, supports self-administration in diverse species, including humans (Henningfield et al., 1983), non-human primates (Goldberg et al., 1981) and rodents (Martellotta et al., 1995; Donny et al., 1998). In agreement with this literature, we report here that freely moving C57BL/6J mice will chronically self-administer an optimal dose of response-dependent nicotine, using nose-poking as the operating procedure. The yoked-control model of self-administration allows discriminating the neurobiological response that occurs as a result of the direct pharmacological effects of a drug, from neuroplasticity that is due to the contingency between a behavioural reaction and drug delivery. By successfully applying this operant paradigm in mice, we reveal that differential neuroadaptation takes place in the nicotinic cholinergic system, depending on whether nicotine is administered actively or passively. Indeed, cytosine-sensitive [¹²⁵I]epibatidine binding differed between self-administering and nicotine-yoked animals in the ventral tegmental area (VTA) and the dorsal lateral geniculate nucleus (DLG), suggesting that these brain regions are critically involved in the processes relating to the acquisition and maintenance of nicotine self-administration.

The increased rate of self-administration observed on days 1 and 2 may be partly attributed to the novelty of the experimental procedure. Similar patterns of increased intake during the initial phase of drug exposure have also been observed elsewhere (Mendizabal et al., 2006). As early as on day 1, however, contingent mice were discriminating between the active and inactive hole, suggesting that the enhanced initial consumption may partly constitute a specific, nicotine-maintained effect on

behaviour. In line with our findings, a pattern of escalated drug intake that levels off in subsequent sessions has also been observed in rats that chronically self-administer nicotine (O'Dell et al., 2007). **Out of a wide range of doses, acute self-administration of nicotine in mice occurs around a narrow window of approximately 0.03 mg/kg/infusion, indicating that rodents will tightly regulate their amount of nicotine intake (Paterson et al., 2003; Pons et al., 2008).** Indeed, titration seems to be an important feature of nicotine self-administration across species, as both adult (Benowitz and Jacob, 1985) and adolescent (Kassel et al., 2007) smokers carefully control their nicotine levels in order to experience the reinforcing effects of the drug. The observed enhanced initial rate of nicotine consumption may thus reflect a learning response at a given level of titration, which rapidly occurred within the first two experimental sessions.

Following day 7, reliable drug-taking behaviour was observed in animals receiving response-dependent nicotine, which was maintained for the remainder of this experiment. Response-contingent animals adjusted their behaviour to obtain a mean drug intake of approximately 0.25 mg/kg/session, which is within the range of nicotine chronically self-administered by rats (Donny et al., 1995; Kenny and Markou, 2006). As demonstrated by cytosine-sensitive [¹²⁵I]epibatidine autoradiography, exposure to this nicotinic dose led to region-specific increases of $\alpha 4\beta 2^*$ nAChRs in the brains of self-administering animals. The upregulation displayed marked regional variability, with **different** areas of the brain participating and showing different sensitivity to upregulation. In this respect, our findings are consistent with previous observations that experimenter-administered nicotine **in rodents** (Marks et al., 1983; Schwartz and Kellar, 1983; Nguyen et al., 2003), as well as nicotine self-administration **by rats**

(Parker et al., 2004), produces regional-specific increases in the density of nicotinic receptors. **The brain areas where contingent nicotine upregulated nAChRs have been shown to be affected by nicotine exposure following a variety of drug administration regimes, including tail vein infusion (Pauly et al., 1991), osmotic minipumps (Nguyen et al., 2003), oral administration (Sparks and Pauly, 1999), and continuous self-administration in the rat (Parker et al., 2004). This suggests that the paradigm of nicotine self-administration we have employed is a valid model for the investigation of nicotine-induced neuroadaptation.** Substantial experimental work has established nAChR upregulation as the hallmark of chronic nicotine treatment. Using intravenous nicotine infusion, it has been consistently demonstrated that nicotine-induced receptor upregulation is a dose and time dependent phenomenon, with the half maximal dose required to induce 50% of region-specific nAChR upregulation **in mice** being approximately 0.5 mg/kg/hr (Marks et al., 1991; Pauly et al., 1991; Marks et al., 2004). In our paradigm, the mean daily amount of self-administered and passively received nicotine was at 0.25 mg/kg/hr. **Therefore, the lack of pronounced upregulation in nicotine-yoked mice is in agreement with the dosing profile for drug induced nAChR increases, and underlines the significance of contingency in nicotinic neuroadaptation, since we observed $\alpha 4\beta 2^*$ nAChR upregulation with smaller, albeit behaviourally relevant doses of nicotine.** Although similar increases might occur in non-contingent animals after longer exposure to nicotine, our data suggest that the sensitivity of nAChRs to upregulation is particularly enhanced during the phase of initial exposure to the drug. The finding that cytisine-sensitive [¹²⁵I]epibatidine binding sites were increased in response-dependent mice that were stably self-administering nicotine, as well as in animals that did not achieve the acquisition criteria, further supports that it is the

contingent relationship between a behavioural response and drug delivery, **rather than the amount of nicotine-intake**, that crucially mediates nicotine-induced neurochemistry during the establishment of self-administration behaviour.

Among the regions that responded differently to active and passive nicotine administration, the VTA is the biological substrate most likely to be involved in the initiation and maintenance of drug-taking behaviour. The VTA is source of the dopaminergic projection to the nucleus accumbens (NAc), and it has been implicated in mediating the reinforcing properties of many drugs of abuse, including nicotine (Di Chiara, 2000). Rats will self-administer nicotine directly into the VTA through intracranial injections, a behaviour that is attenuated by co-infusion of the $\beta 2$ subunit antagonist **dihydro- β -erythroidine**, indicating that nicotine's rewarding effects are exerted through nAChRs in this brain region (Corrigall et al., 1994). Moreover, evidence from studies on gain-of-function $\alpha 4$ nAChR subunit knock-in animals (Tapper et al., 2004), as well as data from $\beta 2$ subunit knock-out mice (Picciotto et al., 1998), further reveals the critical role of VTA $\alpha 4\beta 2^*$ receptors in mediating nicotine reinforcement. Therefore, our data are not only in keeping with several other lines of evidence, but further suggest that **the upregulation of $\alpha 4\beta 2^*$ nAChRs in the VTA is not simply an epiphenomenon of nicotine administration, but a key neurobiological feature that is critical for mediating nicotine-intake.**

A large body of literature suggests that nicotine reinforcement is not only the result of the drug's primary rewarding effects, but also stems from nicotine's ability to establish concurrent stimuli as conditioned reinforcers (reviewed in Chaudhri et al., 2006). In rodents, environmental stimuli promote the rapid acquisition of drug-seeking

behaviour (Caggiula et al., 2002), and the maintenance of nicotine self-administration during saline substitution (Donny et al., 1999; Martin-Garcia et al., 2009). Although the dissociation of nicotine's primary reinforcing, from its reinforcement enhancing effects was not an aim of our study, our autoradiography data are suggestive of a role for the visually paired stimulus in the acquisition of nicotine self-administration. Increased cytosine-sensitive [125 I]epibatidine binding was observed in self-administering mice compared to nicotine yoked animals in the DLG, a brain region that is dedicated to the processing of visual information. In cells of the DLG, $\beta 2$ subunits have been associated with fast latencies of visual responding, and high visually evoked firing rates (Grubb and Thompson, 2004). Moreover, mouse DLG neurons are capable of switching from tonic to burst firing, in order to facilitate signal detection (Grubb and Thompson, 2005). The enhanced density of $\alpha 4\beta 2^*$ nAChRs in this brain area may therefore underlie intense visual information processing, which might contribute to the acquisition of self-administration. **In support of this, we have previously shown that saline-infused mice that receive a visual cue for active nose-poking do not acquire self administration behaviour, implying that nicotine-induced effects on visual processing are important for the acquisition of this behaviour (Trigo et al., 2007; Martin-Garcia et al., 2009).**

Neuronal nAChRs constitute a heterogeneous family of receptors, which, depending on their subunit composition, exhibit distinct physiological and pharmacological properties (reviewed in Dani and Bertrand, 2007). From the present results, we cannot exclude that contingent nicotine preferentially increases $\alpha 4\beta 2^*$ receptor binding, while its passive administration regulates other nicotinic subtypes in a similar manner. Indeed, cytosine-resistant [125 I]epibatidine binding sites correspond to structurally

diverse nAChRs subtypes, which require expression of $\alpha 3$, $\alpha 4$, $\alpha 6$, $\alpha 2$, $\beta 2$, and $\beta 4$ subunits (Gotti et al., 2005; Marks et al., 2006). Although cytosine-resistant nAChR density did not differ between animals receiving nicotine in a response-dependent or passive manner, subtle differences in the regulation of subunit-specific responses to contingent or passive nicotine remain to be examined. Nevertheless, evidence argues against the role of $\alpha 7$ nAChRs in nicotine reinforcement (Walters et al., 2006; Pons et al., 2008). Furthermore, although $\alpha 6$ subunits are involved in acute nicotine self-administration (Pons et al., 2008), autoradiographic studies on the effects of nicotine administration on $\alpha 6^*$ nAChRs have not yet produced conclusive results (Nguyen et al., 2003; Parker et al., 2004; Mugnaini et al., 2006; Even et al., 2008). In addition, $\alpha 3\beta 4^*$ nAChRs are relatively resistant to up-regulation, both *in vivo* and *in vitro* (Wang et al., 1998; Davila-Garcia et al., 2003; Nguyen et al., 2003). It thus seems probable that the effects of operant contingency are depicted as changes in cytosine-sensitive nAChR density in self-administering mice.

Whatever produces neurobiological differences between response-dependent and passively received nicotine, it does not seem to engage dopaminergic D1 and D2 receptors or the dopamine transporters. In the current study, drug administration did not alter D1 receptor or DAT density, and it equally upregulated D2 receptors in contingent and non-contingent animals. As shown by *in vivo* microdialysis, extracellular dopamine levels do not differ between rats self-administering nicotine and nicotine-yoked animals, further suggesting that dopaminergic responses to chronic nicotine administration are independent of response contingency (Rahman et al., 2004). D2 receptors have been implicated in nicotine dependence in both human (McEvoy et al., 1995) and animal experiments (Ikemoto et al., 2006). Radioligand studies,

however, have produced conflicting results as to the effect of chronic nicotine on D2 receptor density. When delivered through osmotic minipumps, nicotine has been shown to decrease (Janson et al., 1992) or produce no differences (Kirch et al., 1992) in D2 receptor density. Therefore, D2 receptor regulation seems to depend on the paradigm of nicotine administration employed, as well as on the drug dose and the duration of treatment.

In conclusion, our results demonstrate the influence of response-dependency on the neurobiological output of nicotine. **Contingent nicotine in self-administering animals produced the typical pattern of region-specific upregulation of $\alpha 4\beta 2^*$ nAChRs**, whereas the administration of nicotine in a passive manner produced little change in the density of cytosine-sensitive receptors. **Importantly, the observation that differential regulation of nAChRs takes place in the VTA and the DLG of self-administering animals, compared with nicotine-yoked mice, suggests that nAChR upregulation in these brain regions is not a by-product of nicotine exposure, but a neurobiological feature that crucially determines the acquisition and maintenance of nicotine self-administration.** Our data add to the increasing evidence that experimenter and self-administered drugs of abuse produce different effects (Hemby et al., 1997; Kuzmin and Johansson, 1999; Donny et al., 2000; Lecca et al., 2007), and suggest that nicotine-induced neuroadaptation crucially depends on the contingent relationship between a subject's response and the delivery of the reinforcer.

ACKNOWLEDGEMENTS: This work was supported by the European Commission (LSHM-CT2004-005166).

AUTHORS CONTRIBUTION: All behavioural experiments were conducted by M. F. Barbano and L. Galeote in R. Maldonado's group, at the University of Pompeu Fabra, Barcelona, Spain. The quantitative autoradiography experiments were conducted in I. Kitchen's group by A. Metaxas and A. Bailey, at the University of Surrey, Guildford, UK.

REFERENCES

Bailey A, Metaxas A, Yoo JH, McGee T, Kitchen I (2008) Decrease of D2 receptor binding but increase in D2-stimulated G-protein activation, dopamine transporter binding and behavioural sensitization in brains of mice treated with a chronic escalating dose 'binge' cocaine administration paradigm. *Eur J Neurosci* 28:759-770.

Benowitz NL, Jacob P, 3rd (1985) Nicotine renal excretion rate influences nicotine intake during cigarette smoking. *J Pharmacol Exp Ther* 234:153-155.

Caggiula AR, Donny EC, Chaudhri N, Perkins KA, Evans-Martin FF, Sved AF (2002) Importance of nonpharmacological factors in nicotine self-administration. *Physiol Behav* 77:683-687.

Chaudhri N, Caggiula AR, Donny EC, Palmatier MI, Liu X, Sved AF (2006) Complex interactions between nicotine and nonpharmacological stimuli reveal multiple roles for nicotine in reinforcement. *Psychopharmacology (Berl)* 184:353-366.

Corrigall WA, Coen KM, Adamson KL (1994) Self-administered nicotine activates the mesolimbic dopamine system through the ventral tegmental area. *Brain Res* 653:278-284.

Dani JA, Bertrand D (2007) Nicotinic Acetylcholine Receptors and Nicotinic Cholinergic Mechanisms of the Central Nervous System. *Annual Review of Pharmacology and Toxicology* 47.

Davila-Garcia MI, Musachio JL, Kellar KJ (2003) Chronic nicotine administration does not increase nicotinic receptors labeled by [¹²⁵I]epibatidine in adrenal gland, superior cervical ganglia, pineal or retina. *Journal of Neurochemistry* 85:1237-1246.

Di Chiara G (2000) Role of dopamine in the behavioural actions of nicotine related to addiction. *European Journal of Pharmacology* 393:295-314.

Donny EC, Caggiula AR, Knopf S, Brown C (1995) Nicotine self-administration in rats. *Psychopharmacology (Berl)* 122:390-394.

Donny EC, Caggiula AR, Mielke MM, Jacobs KS, Rose C, Sved AF (1998) Acquisition of nicotine self-administration in rats: the effects of dose, feeding schedule, and drug contingency. *Psychopharmacology (Berl)* 136:83-90.

Donny EC, Caggiula AR, Rose C, Jacobs KS, Mielke MM, Sved AF (2000) Differential effects of response-contingent and response-independent nicotine in rats. *Eur J Pharmacol* 402:231-240.

Donny EC, Caggiula AR, Mielke MM, Booth S, Gharib MA, Hoffman A, Maldovan V, Shupenko C, McCallum SE (1999) Nicotine self-administration in rats on a progressive ratio schedule of reinforcement. *Psychopharmacology (Berl)* 147:135-142.

Even N, Cardona A, Soudant M, Corringer PJ, Changeux J, Cloez-Tayarani I (2008) Regional differential effects of chronic nicotine on brain $\alpha 4$ -containing and $\alpha 6$ -containing receptors. *Neuroreport* 19:1545-1550.

Franklin KBJ, Paxinos G (2001) The mouse brain in stereotaxic coordinates, 2nd Edition. San Diego: Academic Press.

Goldberg SR, Spealman RD, Goldberg DM (1981) Persistent behavior at high rates maintained by intravenous self-administration of nicotine. *Science* 214:573-575.

Gotti C, Clementi F (2004) Neuronal nicotinic receptors: from structure to pathology. *Progress in Neurobiology* 74:363.

Gotti C, Moretti M, Zanardi A, Gaimarri A, Champtiaux N, Changeux JP, Whiteaker P, Marks MJ, Clementi F, Zoli M (2005) Heterogeneity and selective targeting of neuronal nicotinic acetylcholine receptor (nAChR) subtypes expressed on retinal afferents of the superior colliculus and lateral geniculate nucleus: identification of a new native nAChR subtype $\alpha 3\beta 2(\alpha 5 \text{ or } \beta 3)$ enriched in retinocollicular afferents. *Mol Pharmacol* 68:1162-1171.

Grubb MS, Thompson ID (2004) Visual response properties in the dorsal lateral geniculate nucleus of mice lacking the beta2 subunit of the nicotinic acetylcholine receptor. *J Neurosci* 24:8459-8469.

Grubb MS, Thompson ID (2005) Visual response properties of burst and tonic firing in the mouse dorsal lateral geniculate nucleus. *J Neurophysiol* 93:3224-3247.

Hemby SE, Co C, Koves TR, Smith JE, Dworkin SI (1997) Differences in extracellular dopamine concentrations in the nucleus accumbens during response-dependent and response-independent cocaine administration in the rat. *Psychopharmacology (Berl)* 133:7-16.

Henningfield JE, Miyasato K, Jasinski DR (1983) Cigarette smokers self-administer intravenous nicotine. *Pharmacol Biochem Behav* 19:887-890.

Ikemoto S, Qin M, Liu ZH (2006) Primary reinforcing effects of nicotine are triggered from multiple regions both inside and outside the ventral tegmental area. *J Neurosci* 26:723-730.

Jacobs EH, Smit AB, de Vries TJ, Schoffelmeer AN (2003) Neuroadaptive effects of active versus passive drug administration in addiction research. *Trends Pharmacol Sci* 24:566-573.

Janson AM, Hedlund PB, Hillefors M, von Euler G (1992) Chronic nicotine treatment decreases dopamine D2 agonist binding in the rat basal ganglia. *Neuroreport* 3:1117-1120.

Javitch JA, Blaustein RO, Snyder SH (1984) [3H]mazindol binding associated with neuronal dopamine and norepinephrine uptake sites. *Mol Pharmacol* 26:35-44.

Kassel JD, Greenstein JE, Evatt DP, Wardle MC, Yates MC, Veilleux JC, Eissenberg T (2007) Smoking topography in response to denicotinized and high-yield nicotine cigarettes in adolescent smokers. *J Adolesc Health* 40:54-60.

Kenny PJ, Markou A (2006) Nicotine self-administration acutely activates brain reward systems and induces a long-lasting increase in reward sensitivity. *Neuropsychopharmacology* 31:1203-1211.

Kirch DG, Taylor TR, Creese I, Xu SX, Wyatt RJ (1992) Effect of chronic nicotine treatment and withdrawal on rat striatal D1 and D2 dopamine receptors. *J Pharm Pharmacol* 44:89-92.

Kitchen I, Slowe SJ, Matthes HW, Kieffer B (1997) Quantitative autoradiographic mapping of mu-, delta- and kappa-opioid receptors in knockout mice lacking the mu-opioid receptor gene. *Brain Res* 778:73-88.

Kuzmin A, Johansson B (1999) Expression of c-fos, NGFI-A and secretogranin II mRNA in brain regions during initiation of cocaine self-administration in mice. *Eur J Neurosci* 11:3694-3700.

Lecca D, Cacciapaglia F, Valentini V, Acquas E, Di Chiara G (2007) Differential neurochemical and behavioral adaptation to cocaine after response contingent and noncontingent exposure in the rat. *Psychopharmacology (Berl)* 191:653-667.

Lena I, Matthes H, Kieffer B, Kitchen I (2004) Quantitative autoradiography of dopamine receptors in the brains of micro-opioid receptor knockout mice. *Neurosci Lett* 356:220-224.

Mansvelder HD, McGehee DS (2000) Long-term potentiation of excitatory inputs to brain reward areas by nicotine. *Neuron* 27:349-357.

Mansvelder HD, Keath JR, McGehee DS (2002) Synaptic Mechanisms Underlie Nicotine-Induced Excitability of Brain Reward Areas. *Neuron* 33:905-919.

Marks MJ, Burch JB, Collins AC (1983) Effects of chronic nicotine infusion on tolerance development and nicotinic receptors. *J Pharmacol Exp Ther* 226:817-825.

Marks MJ, Smith KW, Collins AC (1998) Differential agonist inhibition identifies multiple epibatidine binding sites in mouse brain. *J Pharmacol Exp Ther* 285:377-386.

Marks MJ, Whiteaker P, Collins AC (2006) Deletion of the alpha7, beta2, or beta4 nicotinic receptor subunit genes identifies highly expressed subtypes with relatively low affinity for [3H]epibatidine. *Mol Pharmacol* 70:947-959.

Marks MJ, Campbell SM, Romm E, Collins AC (1991) Genotype influences the development of tolerance to nicotine in the mouse. *J Pharmacol Exp Ther* 259:392-402.

Marks MJ, Whiteaker P, Grady SR, Picciotto MR, McIntosh JM, Collins AC (2002) Characterization of [(125) I]epibatidine binding and nicotinic agonist-mediated (86)

Rb(+) efflux in interpeduncular nucleus and inferior colliculus of beta2 null mutant mice. *J Neurochem* 81:1102-1115.

Marks MJ, Rowell PP, Cao JZ, Grady SR, McCallum SE, Collins AC (2004) Subsets of acetylcholine-stimulated $^{86}\text{Rb}^{+}$ efflux and $[^{125}\text{I}]$ -epibatidine binding sites in C57BL/6 mouse brain are differentially affected by chronic nicotine treatment. *Neuropharmacology* 46:1141-1157.

Martellotta MC, Kuzmin A, Zvartau E, Cossu G, Gessa GL, Fratta W (1995) Isradipine inhibits nicotine intravenous self-administration in drug-naive mice. *Pharmacology Biochemistry and Behavior* 52:271-274.

Martin-Garcia E, Barbano MF, Galeote L, Maldonado R (2009) New operant model of nicotine-seeking behaviour in mice. *Int J Neuropsychopharmacol* 12:343-356.

Maskos U, Molles BE, Pons S, Besson M, Guiard BP, Guilloux JP, Evrard A, Cazala P, Cormier A, Mameli-Engvall M, Dufour N, Cloez-Tayarani I, Bemelmans AP, Mallet J, Gardier AM, David V, Faure P, Granon S, Changeux JP (2005) Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors. *Nature* 436:103-107.

McEvoy JP, Freudenreich O, Levin ED, Rose JE (1995) Haloperidol increases smoking in patients with schizophrenia. *Psychopharmacology (Berl)* 119:124-126.

Mendizabal V, Zimmer A, Maldonado R (2006) Involvement of kappa/dynorphin system in WIN 55,212-2 self-administration in mice. *Neuropsychopharmacology* 31:1957-1966.

Mugnaini M, Garzotti M, Sartori I, Pilla M, Repeto P, Heidbreder CA, Tessari M (2006) Selective down-regulation of [(125)I]Y0-alpha-conotoxin MII binding in rat mesostriatal dopamine pathway following continuous infusion of nicotine. *Neuroscience* 137:565-572.

Nashmi R, Xiao C, Deshpande P, McKinney S, Grady SR, Whiteaker P, Huang Q, McClure-Begley T, Lindstrom JM, Labarca C, Collins AC, Marks MJ, Lester HA (2007) Chronic nicotine cell specifically upregulates functional alpha4* nicotinic receptors: basis for both tolerance in midbrain and enhanced long-term potentiation in perforant path. *J Neurosci* 27:8202-8218.

Nguyen HN, Rasmussen BA, Perry DC (2003) Subtype-selective up-regulation by chronic nicotine of high-affinity nicotinic receptors in rat brain demonstrated by receptor autoradiography. *J Pharmacol Exp Ther* 307:1090-1097.

O'Dell LE, Chen SA, Smith RT, Specio SE, Balster RL, Paterson NE, Markou A, Zorrilla EP, Koob GF (2007) Extended access to nicotine self-administration leads to dependence: Circadian measures, withdrawal measures, and extinction behavior in rats. *J Pharmacol Exp Ther* 320:180-193.

Orejarena MJ, Berrendero F, Maldonado R, Robledo P (2009) Differential changes in mesolimbic dopamine following contingent and non-contingent MDMA self-administration in mice. *Psychopharmacology (Berl)* 205:457-466.

Parker SL, Fu Y, McAllen K, Luo J, McIntosh JM, Lindstrom JM, Sharp BM (2004) Up-regulation of brain nicotinic acetylcholine receptors in the rat during long-term self-administration of nicotine: disproportionate increase of the $\alpha 6$ subunit. *Mol Pharmacol* 65:611-622.

Paterson NE, Semenova S, Gasparini F, Markou A (2003) The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice. *Psychopharmacology (Berl)* 167:257-264.

Pauly JR, Marks MJ, Gross SD, Collins AC (1991) An autoradiographic analysis of cholinergic receptors in mouse brain after chronic nicotine treatment. *J Pharmacol Exp Ther* 258:1127-1136.

Perry DC, Davila-Garcia MI, Stockmeier CA, Kellar KJ (1999) Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies. *J Pharmacol Exp Ther* 289:1545-1552.

Picciotto MR, Zoli M, Rimondini R, Lena C, Marubio LM, Pich EM, Fuxe K, Changeux JP (1998) Acetylcholine receptors containing the $\beta 2$ subunit are involved in the reinforcing properties of nicotine. *Nature* 391:173-177.

Pidoplichko VI, DeBiasi M, Williams JT, Dani JA (1997) Nicotine activates and desensitizes midbrain dopamine neurons. *Nature* 390:401-404.

Plaza-Zabala A, Martin-Garcia E, de Lecea L, Maldonado R, Berrendero F (2010) Hypocretins regulate the anxiogenic-like effects of nicotine and induce reinstatement of nicotine-seeking behavior. *J Neurosci* 30:2300-2310.

Pons S, Fattore L, Cossu G, Tolu S, Porcu E, McIntosh JM, Changeux JP, Maskos U, Fratta W (2008) Crucial role of alpha4 and alpha6 nicotinic acetylcholine receptor subunits from ventral tegmental area in systemic nicotine self-administration. *J Neurosci* 28:12318-12327.

Rahman S, Zhang J, Engleman EA, Corrigall WA (2004) Neuroadaptive changes in the mesoaccumbens dopamine system after chronic nicotine self-administration: a microdialysis study. *Neuroscience* 129:415-424.

Schwartz RD, Kellar KJ (1983) Nicotinic cholinergic receptor binding sites in the brain: regulation in vivo. *Science* 220:214-216.

Soria G, Mendizabal V, Tourino C, Robledo P, Ledent C, Parmentier M, Maldonado R, Valverde O (2005) Lack of CB1 cannabinoid receptor impairs cocaine self-administration. *Neuropsychopharmacology* 30:1670-1680.

Sparks JA, Pauly JR (1999) Effects of continuous oral nicotine administration on brain nicotinic receptors and responsiveness to nicotine in C57Bl/6 mice. *Psychopharmacology (Berl)* 141:145-153.

Tapper AR, McKinney SL, Nashmi R, Schwarz J, Deshpande P, Labarca C, Whiteaker P, Marks MJ, Collins AC, Lester HA (2004) Nicotine activation of $\alpha 4^*$ receptors: sufficient for reward, tolerance, and sensitization. *Science* 306:1029-1032.

Trigo JM, Zimmer A, Maldonado R (2009) Nicotine anxiogenic and rewarding effects are decreased in mice lacking beta-endorphin. *Neuropharmacology* 56:1147-1153.

Trigo JM, Renoir T, Lanfumey L, Hamon M, Lesch KP, Robledo P, Maldonado R (2007) 3,4-methylenedioxymethamphetamine self-administration is abolished in serotonin transporter knockout mice. *Biological Psychiatry* 62:669-679.

Walters CL, Brown S, Changeux JP, Martin B, Damaj MI (2006) The $\beta 2$ but not $\alpha 7$ subunit of the nicotinic acetylcholine receptor is required for nicotine-conditioned place preference in mice. *Psychopharmacology (Berl)* 184:339-344.

Wang F, Nelson ME, Kuryatov A, Olale F, Cooper J, Keyser K, Lindstrom J (1998) Chronic nicotine treatment up-regulates human $\alpha 3 \beta 2$ but not $\alpha 3 \beta 4$ acetylcholine receptors stably transfected in human embryonic kidney cells. *J Biol Chem* 273:28721-28732.

Whiteaker P, Jimenez M, McIntosh JM, Collins AC, Marks MJ (2000) Identification of a novel nicotinic binding site in mouse brain using $[(125)\text{I}]\text{-epibatidine}$. *Br J Pharmacol* 131:729-739.

TABLES

Region	Cytisine-sensitive [¹²⁵ I]epibatidine binding (fmol/mg tissue)			% change in binding	
	Saline	Contingent	Non Contingent	saline vs. contingent	saline vs. non contingent
<i>Habenulo-interpeduncular tract</i>					
Medial habenular nucleus (n=6)	7.1 ± 1.8	8.6 ± 2.1	5.9 ± 1.5	20.6	-17.0
Fasciculus retroflexus (n=6)	9.2 ± 1.3	11.2 ± 2.1	11.3 ± 3.4	22.6	23.5
Interpeduncular nucleus (n=6)	10.8 ± 6.0	12.3 ± 3.6	9.9 ± 3.4	13.5	-8.1
<i>Dopaminergic regions</i>					
Caudate Putamen (n=10-11)	10.7 ± 0.6	11.4 ± 0.5	10.8 ± 0.4	6.6	0.9
Nucleus accumbens, core (n=9-11)	7.3 ± 0.6	8.0 ± 0.4	7.3 ± 0.3	9.9	1.1
Nucleus accumbens, shell (n=9-11)	7.6 ± 0.6	7.9 ± 0.4	7.5 ± 0.3	3.9	-1.3
Substantia nigra, pars compacta (n=9-11)	17.2 ± 1.3	18.7 ± 1.0	17.9 ± 1.2	8.7	4.1
Ventral tegmental area (n=9-11)	16.4 ± 1.2	20.4 ± 1.0*	17.0 ± 1.0 [#]	24.3	3.4
<i>Optic tract regions</i>					
Visual cortex (n=10-11)	9.2 ± 0.4	9.3 ± 0.4	8.8 ± 0.6	1.5	-3.9
Superficial gray layer of the superior colliculus (n=9-11)	13.4 ± 1.2	18.2 ± 2.1*	17.2 ± 2.3*	36.2	28.7
Dorsal lateral geniculate nucleus (n=10-11)	20.6 ± 0.9	27.8 ± 2.4***	23.4 ± 1.5 [#]	35.0	13.6
Ventral lateral geniculate nucleus (n=10-11)	17.3 ± 0.7	24.6 ± 1.8***	21.5 ± 1.5*	42.2	24.3
<i>Other regions</i>					
Accessory olfactory bulb (n=6-11)	6.5 ± 0.8	9.3 ± 2.0	9.2 ± 1.0	43.1	41.5
Insular cortex (n=10-11)	8.8 ± 0.3	9.4 ± 0.5	9.1 ± 0.4	6.8	3.4
Cingulate cortex (n=10-11)	9.5 ± 0.5	9.7 ± 0.5	9.1 ± 0.4	2.6	-3.4
Olfactory tubercle (n=10-11)	8.9 ± 1.0	9.8 ± 0.7	9.9 ± 0.8	10.5	11.6
Lateral posterior thalamic nucleus (n=10-11)	18.8 ± 0.9	22.6 ± 1.1*	20.6 ± 1.1	19.8	9.6
Posterior thalamic nuclear group (n=10-11)	18.3 ± 0.9	21.4 ± 1.8*	20.7 ± 1.6	17.2	13.2
Medial geniculate nucleus (n=8-11)	19.7 ± 1.1	21.4 ± 1.0	20.3 ± 1.3	8.7	2.8
Intermediate gray layer of the superior colliculus (n=9-11)	12.7 ± 1.0	15.8 ± 0.8	13.8 ± 1.2	24.2	8.9
Anteroventral thalamic nucleus (n=9-11)	30.4 ± 0.8	31.2 ± 1.6	29.1 ± 2.1	2.5	-4.4
Mean				17.2	7.3

Table 1 Quantitative autoradiography of cytosine-sensitive [¹²⁵I]epibatidine binding in nicotine contingent, non contingent, and saline treated animals

Values of cytosine-sensitive [¹²⁵I]epibatidine binding represent mean ± SEM in brain regions of 6 - 11 animals per group. Self administered nicotine region-specifically increased α4β2* nAChRs in the dorsal lateral geniculate nucleus (DLG) and the ventral tegmental area (VTA) of self-administering mice, compared to non-contingent animals and to saline controls. *P<0.05, ***P<0.001 vs. saline controls, [#]P<0.05 vs. contingent values, LSD post hoc.

Region	Cytisine-resistant [¹²⁵ I]epibatidine binding (fmol/mg tissue)			% change in binding	
	Saline	Contingent	Non Contingent	saline vs. contingent	saline vs. non contingent
<i>Habenulo-interpenducular tract</i>					
Medial habenular nucleus	84.1 ± 7.8	85.9 ± 7.2	81.1 ± 8.2	2.1	-3.5
Fasciculus retroflexus	65.7 ± 5.6	64.6 ± 6.9	63.8 ± 5.3	-1.7	-2.9
Interpeduncular nucleus	101.2 ± 6.1	99.3 ± 6.5	95.1 ± 6.9	-1.9	-6.0
<i>Dopaminergic regions</i>					
Caudate Putamen	2.1 ± 0.2	2.2 ± 0.2	2.2 ± 0.2	0.5	2.8
Nucleus accumbens, core	2.0 ± 0.3	2.2 ± 0.2	2.0 ± 0.2	11.1	-1.5
Nucleus accumbens, shell	2.2 ± 0.2	2.1 ± 0.2	2.0 ± 0.2	-0.9	-5.6
Substantia nigra, pars compacta	5.5 ± 0.9	4.0 ± 0.7	3.7 ± 0.5*	-26.2	-32.1
Ventral tegmental area	6.8 ± 0.3	6.2 ± 0.5	5.3 ± 0.5	-9.7	-22.6
<i>Optic tract regions</i>					
Visual cortex	0.6 ± 0.1	0.7 ± 0.1	0.4 ± 0.1	4.8	-29.0
Superficial gray layer of the superior colliculus	19.1 ± 1.0	19.3 ± 1.5	15.1 ± 1.2***	1.2	-20.6
Dorsal lateral geniculate nucleus	12.2 ± 0.5	11.4 ± 0.9	12.7 ± 1.0	-5.8	4.3
Ventral lateral geniculate nucleus	12.4 ± 0.6	11.1 ± 1.1	12.7 ± 1.4	-10.4	2.6
<i>Other regions</i>					
Accessory olfactory bulb	17.2 ± 1.0	15.9 ± 1.2	18.2 ± 3.3	-7.6	6.4
Insular cortex	0.8 ± 0.1	0.9 ± 0.1	0.7 ± 0.1	14.6	-17.1
Cingulate cortex	0.7 ± 0.1	0.6 ± 0.1	0.6 ± 0.1	-8.7	-13.0
Olfactory tubercle	1.2 ± 0.2	1.8 ± 0.2	1.4 ± 0.2	46.7	13.3
Lateral posterior thalamic nucleus	4.6 ± 0.3	4.7 ± 0.4	4.1 ± 0.3	2.9	-11.0
Posterior thalamic nuclear group	2.8 ± 0.2	2.9 ± 0.2	2.8 ± 0.3	5.5	1.8
Medial geniculate nucleus	3.2 ± 0.3	3.2 ± 0.3	2.8 ± 0.5	0.9	-13.1
Intermediate gray layer of the superior colliculus	5.3 ± 1.1	2.7 ± 0.3**	2.3 ± 0.5***	-49.5	-56.9
Anteroventral thalamic nucleus	4.4 ± 0.6	4.9 ± 0.5	4.8 ± 0.4	11.6	8.6
Mean				-1.1	-10.1

Table 2 Quantitative autoradiography of cytosine-resistant [¹²⁵I]epibatidine binding in nicotine contingent, non contingent, and saline treated animals

Values of cytosine-resistant [¹²⁵I]epibatidine binding represent mean ± SEM in brain regions of 6 - 11 animals per group. A significant treatment x region interaction effect on cytosine-resistant nAChR density was observed following the administration of nicotine. No differences were observed between animals that stably responded for nicotine, and mice that did not achieve acquisition criteria. *P<0.05, **P<0.01, ***P<0.001 vs. saline controls, LSD post hoc.

Region	³ H]raclopride specific binding (fmol/mg tissue)			% change in binding	
	Saline	Contingent	Non Contingent	saline vs. contingent	saline vs. non contingent
Olfactory tubercle	88.9 ± 9.9	108.9 ± 7.0	104.4 ± 4.6	22.5	17.4
Nucleus accumbens					
<i>Core</i>	76.3 ± 7.6	83.9 ± 12.1	85.7 ± 5.2	10.0	12.4
<i>Shell</i>	74.3 ± 8.5	94.1 ± 6.1	90.6 ± 5.7	26.6	22.0
Caudate Putamen					
<i>Rostral part</i>	122.7 ± 12.7	143.0 ± 10.7	143.7 ± 4.2	16.6	17.1
<i>Caudal part</i>	127.1 ± 6.2	137.3 ± 13.5	148.6 ± 5.1	8.0	16.9
Ventral tegmental area	32.3 ± 2.7	38.5 ± 1.9	33.9 ± 2.8	19.4	4.9
Substantia nigra, pars compacta	33.6 ± 2.6	43.0 ± 4.3	38.9 ± 2.2	28.0	16.0
Mean				18.7	15.2

Table 3 Quantitative autoradiography of D2 receptor binding in nicotine contingent, non contingent, and saline treated animals

Values represent the mean specific binding of [³H]raclopride ± SEM in brain regions of 6 animals per group. A small level of D2 receptor upregulation was observed following self-administered and passively received nicotine, but no individual region significant increases were observed between groups.

Region	³ H]SCH23390 specific binding (fmol/mg tissue)			% change in binding	
	Saline	Contingent	Non Contingent	saline vs. contingent	saline vs. non contingent
Nucleus accumbens					
<i>Core</i>	186.4 ± 24.7	248.4 ± 30.0	246.4 ± 48.2	33.3	32.2
<i>Shell</i>	193.6 ± 23.8	237.0 ± 27.4	236.0 ± 44.9	22.5	21.9
Caudate Putamen	328.1 ± 16.4	359.2 ± 24.5	363.0 ± 37.5	9.5	10.6
Olfactory tubercle	309.1 ± 22.6	335.2 ± 31.0	339.9 ± 48.2	8.5	10.0
Endopiriform nucleus, dorsal	65.3 ± 3.5	80.2 ± 6.0	68.2 ± 6.4	22.8	4.5
Clastrum	51.2 ± 5.5	55.6 ± 2.2	48.3 ± 6.5	8.7	-5.6
Amygadala, total	27.6 ± 2.3	30.9 ± 2.1	28.7 ± 1.8	12.0	3.8
Ventral tegmental area	27.1 ± 3.9	37.6 ± 2.9	36.8 ± 2.8	38.5	35.7
Substantia nigra	168.7 ± 15.3	165.3 ± 14.1	190.3 ± 19.2	-2.0	12.9
Mean				17.1	14.0

Table 4 Quantitative autoradiography of D1 receptor binding in nicotine contingent, non contingent, and saline treated animals

Values represent the mean specific binding of [³H]SCH23390 ± SEM in brain regions of 6 animals per group. Nicotine self-administration had no effect on D1 receptor density.

Region	³ H]mazindol specific binding (fmol/mg tissue)			% change in binding	
	Saline	Contingent	Non Contingent	saline vs. contingent	saline vs. non contingent
Olfactory tubercle	281.6 ± 41.5	251.0 ± 19.2	298.2 ± 54.6	-10.9	5.9
Nucleus accumbens					
<i>Core</i>	159.1 ± 25.7	173.0 ± 22.1	219.3 ± 34.3	8.7	37.8
<i>Shell</i>	193.2 ± 33.0	198.5 ± 14.0	227.6 ± 42.4	2.8	17.8
Caudate Putamen					
<i>Rostral part</i>	375.2 ± 52.2	447.8 ± 35.4	461.8 ± 38.0	19.4	23.1
<i>Caudal part</i>	367.3 ± 55.3	421.2 ± 29.7	367.9 ± 30.8	14.7	0.2
Ventral tegmental area	121.1 ± 21.2	165.8 ± 10.5	162.7 ± 16.2	36.9	34.4
Substantia nigra, pars compacta	118.2 ± 13.0	128.4 ± 17.7	117.8 ± 11.6	8.6	-0.3
Mean				11.9	19.9

Table 5 Quantitative autoradiography of dopamine transporter binding in nicotine contingent, non contingent, and saline treated animals

Values represent the mean specific binding of [³H]mazindol ± SEM in brain regions of 6 animals per group. Nicotine self-administration had no effect on dopamine transporter density.

LEGENDS TO FIGURES

Legend to Figure 1 Acquisition and maintenance of nicotine self-administration in nicotine contingent and non-contingent C57BL/6J mice. Data are expressed as mean $\pm$ SEM of the number of nose pokes in the active and the inactive holes during the 1-hour sessions performed over 12 days at 0.03 mg/kg/infusion. **Following day 7, reliable drug-taking behaviour was observed in animals receiving response-dependent nicotine, which was maintained throughout the duration of this experiment.** The mean cumulative nicotine intake throughout the training sessions was at 0.25 ± 0.04 mg/kg/hr. $n=11$ for nicotine-treated animals, $n=10$ for saline-yoked mice.

Legend to Figure 2 Computer-enhanced colour autoradiograms of total, cytosine-resistant, and non-specific [125 I]epibatidine binding in coronal sections from saline-treated C57BL/6J mouse brain. Adjacent sections were incubated for 2 hrs with 100 pM of [125 I]epibatidine alone (first column) or in the presence of 20 nM cytosine (second column), and 300 μ M (–) nicotine hydrogen tartrate (third column). Non-specific binding was indistinguishable from film background. The majority of [125 I]epibatidine binding sites were of the cytosine-sensitive, $\alpha 4\beta 2^*$ subtype. High levels of cytosine-resistant [125 I]epibatidine binding were observed in the medial habenula, fasciculus retroflexus, and interpeduncular nucleus. Sections were apposed to Kodak BioMax MR-1 film for a period of 6-24 hours. The colour bar indicates a pseudo-colour interpretation of black and white image density, calibrated in fmol/mg of tissue equivalent. The arrows point to areas of measurement for the Caudate Putamen (CPu), Medial Habenula (MHb), Lateral Posterior Thalamic Nucleus (LPMR), Posterior Thalamic Nuclear Group (Po), Dorsal and Ventral Lateral Geniculate Nuclei (DLG & VLG), Ventral Tegmental Area (VTA), Substantia Nigra,

pars compacta (SNc), Fasciculus retroflexus (fr), Interpeduncular Nucleus (IP), Superficial Gray layer of the Superior Colliculus (SuG), and the Medial Geniculate Nucleus (MG).

Legend to Figure 3 Representative autoradiograms of heteromeric nAChR binding in coronal brain sections from nicotine contingent, non contingent, and saline treated animals. The effects of response-contingency on nicotinic receptor binding populations are shown at the levels of thalamus (bregma -2.06 mm) and the ventral tegmental area (bregma -3.16), following self-administered or passively received nicotine. $\alpha 4\beta 2^*$ receptor expression was calculated after subtraction of specific cytosine-resistant [125 I]epibatidine binding from total [125 I]epibatidine binding. Response-dependent nicotine increased $\alpha 4\beta 2^*$ receptor binding in the dorsal geniculate nucleus and the ventral tegmental area of self-administering mice, compared to yoked animals. The colour bar indicates a pseudo-colour interpretation of black and white image density, calibrated in fmol/mg of tissue equivalent.

Legend to Figure 4 Computer-enhanced colour autoradiograms of dopamine D2 (A) and D1 receptors (B), and of DA transporters (C), in coronal brain sections from nicotine contingent, non contingent, and saline treated animals. Sections were labelled with 4nM [3 H]raclopride, [3 H]SCH23390, and [3 H]mazindol, for D2 and D1 receptors, and for the dopamine transporters, respectively. The horizontal panels show adjacent sections cut at the level of the caudate putamen, and of the ventral tegmental area. Sections were apposed to Kodak BioMax MR-1 film for a period of 5-6 weeks. Specific binding was calculated after subtraction of non-specific binding images from total binding images. No change in D1 and DAT binding was observed among groups.

The colour bars indicate a pseudo-colour interpretation of black and white image density, calibrated in fmol/mg of tissue equivalent.

Contingent nicotine (A)

Yoked nicotine (B)

Yoked saline (C)

fmol/mg	Total [¹²⁵ I]epibatidine binding	Cytisine-resistant [¹²⁵ I]epibatidine binding	Non-specific binding
---------	---	--	-------------------------